LIke ThisLIke ThisLIke This

Respiratory Diseases Research

As a charter member of the Therapeutics Development Network of the Cystic Fibrosis Foundation, the Division of Respiratory Diseases is involved in the development and early clinical trials of novel therapeutics for CF, including:
  • A small peptide antibiotic administered via inhalation
  • The use of inhaled tobramycin in young children
  • An inhaled form of an anti-inflammatory cytokine
  • An inhaled peptide that increases epithelial cell chloride transport
  • A novel inhaled mucolytic
  • An oral leukotriene receptor antagonist
  • A novel form of pancreatic enzyme supplementation
  • An oral agent that increases the expression of mutant CFTR at the cell surface
  • Gene therapy

In addition, the Division has been or is involved studies of:

  • Quality of life before and after lung transplantation
  • Prednisone during hospitalization for an exacerbation of lung disease
  • Induced sputum as an outcome measure in infants and young children
  • A DHA-containing infant formula
  • Once-daily v. thrice-daily tobramycin during hospitalization for an exacerbation of lung disease
  • Modifier genes and their influence on the clinical severity of CF
  • CF studies examining the natural history of pulmonary function in infants and young children
  • Growth hormone
  • The relationship of Pseudomonas aeruginosa to the severity of lung disease

Featured researchers in the Division of Respiratory Diseases hold faculty appointments at Harvard Medical School.

Latest Research in Respiratory Diseases:

Norma Gerard, PhD Inflammatory response
Christopher Hug, MD, PhD Airway dysfunction
Pyong Woo Park, PhD Extracellular matrix
LIke ThisLIke ThisLIke This